User profiles for R. J. Mather

Robert Mather

Pfizer, Inc.
Verified email at pfizer.com
Cited by 3022

Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1. 1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.

…, AN Nguyen, J Aiyar, DC Hanson, RJ Mather… - Molecular …, 1994 - ASPET
We have analyzed the biophysical and pharmacological properties of five cloned K+ (Kv)
channels (Kv1.1, Kv1.2, Kv1.3, Kv1.5, and Kv3.1) stably expressed in mammalian cell lines. Kv1…

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

…, RS Hurst, LA Lebel, Y Lu, RS Mansbach, RJ Mather… - …, 2007 - Elsevier
The preclinical pharmacology of the α4β2 nicotinic acetylcholine receptor (nAChR) partial
agonist varenicline, a novel smoking cessation agent is described. Varenicline binds with …

[HTML][HTML] The CHRNA5–A3–B4 gene cluster and smoking: from discovery to therapeutics

…, AE Taylor, NJ Timpson, PJ Kenny, RJ Mather… - Trends in …, 2016 - cell.com
Genome-wide association studies (GWASs) have identified associations between the
CHRNA5–CHRNA3–CHRNB4 gene cluster and smoking heaviness and nicotine dependence. …

Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine …

…, E Tseng, EQ Wang, RJ Mather… - British journal of …, 2010 - Wiley Online Library
Background and purpose: Smoking cessation trials with three high‐affinity partial agonists
of α4β2 neuronal nicotinic acetylcholine receptors (nAChRs) have demonstrated differences …

Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivo

…, J Mukherjee, YE Moore, RJ Mather… - Journal of …, 2015 - Soc Neuroscience
GABA A receptors form Cl − permeable channels that mediate the majority of fast synaptic
inhibition in the brain. The K + /Cl − cotransporter KCC2 is the main mechanism by which …

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1. 3 and suppress T cell activation.

…, MS Biggers, PC Canniff, CB Donovan, RJ Mather… - Molecular …, 1996 - ASPET
The nonpeptide agent CP-339,818 (1-benzyl-4-pentylimino-1,4-dihydroquinoline) and two
analogs (CP-393,223 and CP-394,322) that differ only with respect to the type of substituent …

Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the …

…, RS Hurst, N Maklad, RJ Mather… - Journal of medicinal …, 2010 - ACS Publications
A novel α7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
(24, CP-810,123), has been identified as a potential treatment for cognitive deficits …

Remote digital monitoring for medical product development

…, C Leptak, Q Liu, H Manji, RJ Mather… - Clinical and …, 2021 - Wiley Online Library
The use of digital health products has gained considerable interest as a new way to improve
therapeutic research and development. Although these products are being adopted by …

The small molecule CLP257 does not modify activity of the K+–Cl co-transporter KCC2 but does potentiate GABAA receptor activity

…, J Holenz, ME Duggan, J Dunlop, RJ Mather… - Nature Medicine, 2017 - nature.com
… Robert J Mather … Heike J Wobst, Stephen Zicha, Jörg Holenz, Mark E Duggan, John
Dunlop, Robert J Mather, Qi Wang & Nicholas J Brandon … Robert J Mather

UK‐78,282, a novel piperidine compound that potently blocks the Kv1. 3 voltage‐gated potassium channel and inhibits human T cell activation

DC Hanson, A Nguyen, RJ Mather… - British journal of …, 1999 - Wiley Online Library
UK‐78,282, a novel piperidine blocker of the T lymphocyte voltage‐gated K + channel, Kv1.3,
was discovered by screening a large compound file using a high‐throughput 86 Rb efflux …